The Trevo device, a new stent retriever, may be utilized in patients with large cerebral artery occlusion.
Methods:
Fifty patients with large cerebral artery occlusion and treated with the Trevo device were analyzed. Patients may have received intravenous thrombolysis as a bridging concept in addition to thrombectomy. Outcome and recanalization parameters were documented using the National Institutes of Health Scale, the modified Ranking Scale (mRS) and Thrombolysis in Cerebral Infarction (TICI) score.
Results:
In all, 82% (95% confidence interval [CI]: 69%-91%) were documented with TICI 2b and 3. Good clinical outcome after 90 days (mRS ≤ 2) was assessed in 61% (95% CI: 46%-75%). Symptomatic intracerebral hemorrhage occurred in 6 patients (12%, 95% CI: 1%-17%). The overall mortality rate was 14% (95% CI: 6%-27%).
Conclusion:
Thrombectomy with the new stent retriever device is feasible and effective and has an acceptable risk of intra-cerebral hemorrhage even in combination with pharmacological revascularization techniques.
RhaJHSaverJL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38(3):967–973.
2.
NogueiraRGLiebeskindDSSungG. Predictors of good clinical outcomes, mortality, and successful revascularization in patients with acute ischemic stroke undergoing thrombectomy: pooled analysis of the mechanical embolus removal in cerebral ischemia (MERCI) and multi MERCI trials. Stroke. 2009;40(12):3777–3783.
3.
KnauerKHuberR. Fibrinolysis and beyond: bridging the gap between local and systemic clot removal. Front Neurol. 2011;2:7.
4.
del ZoppoGJHigashidaRTFurlanAJPessinMSRowleyHAGentM. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in acute cerebral thromboembolism. Stroke. 1998;29(1):4–11.
5.
OgawaAMoriEMinematsuK. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke. 2007;38(10):2633–2639.
6.
RahmeRAbruzzoTAMartinRH. Is intra-arterial thrombolysis beneficial for M2 occlusions? Subgroup analysis of the PROACT-II trial. Stroke. 2013;44(1):240–2.
7.
Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-PA stroke study group. N Engl J Med. 1995;333(24):1581–1587.
8.
RiedelCHZimmermannPJensen-KonderingUStingeleRDeuschlGJansenO. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke. 2011;42(6):1775–1777.
9.
SaqqurMMolinaCASalamA. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study. Stroke. 2007;38(1):69–74.
10.
SaqqurMUchinoKDemchukAM. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007;38(3):948–954.
11.
SmithWSSungGSaverJ. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008;39(4):1205–1212.
12.
ButcherKSParsonsMMacGregorL. Refining the perfusion–diffusion mismatch hypothesis. Stroke. 2005;36(6):1153–1159.
13.
ChenFNiYC. Magnetic resonance diffusion–perfusion mismatch in acute ischemic stroke: an update. World J Radiol. 2012;4(3):63–74.
14.
FieldsJDLindsayKLiuKCNesbitGMLutsepHL. Mechanical thrombectomy for the treatment of acute ischemic stroke. Expert Rev Cardiovasc Ther. 2010;8(4):581–592.
15.
HigashidaRFurlanARobertsH. Trial design and reporting standards for intraarterial cerebral thrombolysis for acute ischemic stroke. J Vasc Interv Radiol. 2003;14(9 pt 2):S493–S494.
16.
HackeWDonnanGFieschiC. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–774.
17.
WardlawJMSandercockPABergeE. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke. 2003;34(6):1437–1442.
18.
MicieliGMarcheselliSTosiPA. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag. 2009;5(1):397–409.
19.
StemerALydenP. Evolution of the thrombolytic treatment window for acute ischemic stroke. Curr Neurol Neurosci Rep. 2010;10(1):29–33.
20.
San RomanLObachVBlascoJ. Single-center experience of cerebral artery thrombectomy using the TREVO device in 60 patients with acute ischemic stroke. Stroke. 2012;43(6):1657–1659.
21.
BroussalisETrinkaEHitzlWWallnerAChroustVKiller-OberpfalzerM. Comparison of stent-retriever devices versus the Merci retriever for endovascular treatment of acute stroke. AJNR Am J Neuroradiol. 2013;34(2):366–372.
22.
WahlgrenNAhmedNDavalosA. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–282.
23.
STATISTICA, data analysis software system, version 10. www.statsoft.com.
SchellingerPDKohrmannMHackeW. Thrombolytic therapy for acute stroke. Handb Clin Neurol. 2009;94:1155–1193.
26.
NogueiraRGLevyEIGounisMSiddiquiAH. The Trevo device: preclinical data of a novel stroke thrombectomy device in two different animal models of arterial thrombo-occlusive disease. J Neurointerv Surg. 2012;4(4):295–300.
27.
MendoncaNFloresAPagolaJ. Trevo system: single-center experience with a novel mechanical thrombectomy device. J Neuroimaging. 2013;23(1):7–11.
28.
NogueiraRGLutsepHLGuptaR. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012;380(9849):1231–1240.
29.
MokinMDumontTMVeznedarogluE. Solitaire FR thrombectomy for acute ischemic stroke: retrospective multicenter analysis of early postmarket experience after FDA approval. Neurosurgery. 2013;73(1):19–26.
30.
ParkHHwangGJJinSC. A retrieval thrombectomy technique with the Solitaire stent in a large cerebral artery occlusion. Acta Neurochir (Wien). 2011;153(8):1625–1631.
31.
CastanoCDoradoLGuerreroC. Mechanical thrombectomy with the Solitaire AB device in large artery occlusions of the anterior circulation: a pilot study. Stroke. 2010;41(8):1836–1840.
MiteffFFaulderKCGohACSteinfortBSSueCHarringtonTJ. Mechanical thrombectomy with a self-expanding retrievable intracranial stent (Solitaire AB): experience in 26 patients with acute cerebral artery occlusion. AJNR Am J Neuroradiol. 2011;32(6):1078–1081.
34.
StampflSHartmannMRinglebPAHaehnelSBendszusMRohdeS. Stent placement for flow restoration in acute ischemic stroke: a single-center experience with the Solitaire stent system. AJNR Am J Neuroradiol. 2011;32(7):1245–1248.
35.
GrallaJSchrothGRemondaL. A dedicated animal model for mechanical thrombectomy in acute stroke. AJNR Am J Neuroradiol. 2006;27(6):1357–1361.
36.
AlbertsMJLatchawRESelmanWR. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke. 2005;36(7):1597–1616.
37.
SaverJLJahanRLevyEI. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012;380(9849):1241–1249.
38.
ShiZSLohYWalkerGDuckwilerGRMerciMulti MI. Clinical outcomes in middle cerebral artery trunk occlusions versus secondary division occlusions after mechanical thrombectomy: pooled analysis of the mechanical embolus removal in cerebral ischemia (MERCI) and multi MERCI trials. Stroke. 2010;41(5):953–960.
39.
GreenDWSanchezLAParodiJCGeraghtyPJFerreiraLMSicardGA. Acute thromboembolic events during carotid artery angioplasty and stenting: etiology and a technique of neurorescue. J Endovasc Ther. 2005;12(3):360–365.
40.
BroderickJPPaleschYYDemchukAM. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893–903.
RukshinVAzarbalBFinkelsteinA. Effects of GP IIb/IIIa receptor inhibitor tirofiban (aggrastat) in ex vivo canine arteriovenous shunt model of stent thrombosis. J Cardiovasc Pharmacol. 2003;41(4):615–624.
43.
KimJWJeonPKimGMBangOYByunHSKimKH. Local intraarterial tirofiban after formation of anterograde flow in patients with acute ischemic stroke: preliminary experience and short term follow-up results. Clin Neurol Neurosurg. 2012;114(10):1316–1319.
44.
SeitzRJSukiennikJSieblerM. Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban. Neurol Int. 2012;4(2):e9.
45.
KellertLHametnerCRohdeS. Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome. Stroke. 2013;44(5):1453–1455.
46.
ShiZSLohYWalkerGDuckwilerGRMerciMulti MI. Endovascular thrombectomy for acute ischemic stroke in failed intravenous tissue plasminogen activator versus non-intravenous tissue plasminogen activator patients: revascularization and outcomes stratified by the site of arterial occlusions. Stroke. 2010;41(6):1185–11892.
47.
CicconeAValvassoriLNichelattiM. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368(10):904–913.
48.
KidwellCSJahanRAlgerJR. Design and rationale of the mechanical retrieval and recanalization of stroke clots using embolectomy (MR RESCUE) trial [published online September 13, 2012]. Int J Stroke. 2012.
49.
KidwellCSJahanRGornbeinJ. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368(10):914–923.
